The Untapped Specialty Pharmacy Opportunity for Rural Hospitals

Critical Access Hospitals (CAHs), Rural Referral Centers (RRCs), and Sole Community Hospitals (SCHs) play a critical role in maintaining access to care in rural and underserved communities. Many participate in the 340B Drug Pricing Program, operate outpatient or community pharmacies, provide oncology and infusion services, and manage patients receiving increasingly complex and high-cost medications.

Yet there is another question these hospitals should be asking:

What happens to the specialty prescription after the patient leaves the hospital or clinic?

In many cases, a hospital may provide the physician, the diagnosis, the laboratory monitoring, the infusion services, and the ongoing clinical care—only for a specialty prescription to be dispensed by an outside pharmacy.

For CAHs, RRCs, and SCHs already investing in pharmacy and specialty-related clinical services, that may represent an opportunity worth evaluating.

You May Already Have More of the Infrastructure Than You Think

Building a specialty pharmacy program can sound like an enormous undertaking. For some organizations, it will be. But hospitals shouldn't automatically assume they would be starting from scratch.

A hospital may already have several of the foundational pieces in place, including:

• An outpatient or community pharmacy

• An established 340B program

• Oncology, rheumatology, gastroenterology, neurology, or other specialty services

• An infusion center

• Pharmacist involvement in complex medication management

• Medication access or financial-assistance programs

• Existing relationships with specialty prescribers

• Experience managing high-cost medications and vulnerable patient populations

The more useful question may not be, “Should we build a specialty pharmacy?”

It may be, “How much of the specialty pharmacy infrastructure do we already have, and what would it take to close the remaining gaps?”

That is a very different conversation.

The Opportunity Goes Beyond Drug Revenue

The potential value of an internal specialty pharmacy program isn't limited to dispensing revenue.

Specialty patients frequently require significant coordination among prescribers, pharmacists, nurses, payers, manufacturers, laboratories, and financial-assistance programs. When the dispensing pharmacy operates outside the health system, another organization becomes responsible for a critical part of that patient's care.

Bringing appropriate specialty pharmacy services into the health system may create opportunities to improve continuity of care, strengthen communication between pharmacists and prescribers, reduce fragmentation, and provide patients with a more coordinated experience.

For eligible 340B covered entities, there may also be important financial considerations. But the opportunity needs to be evaluated carefully rather than assuming every specialty prescription can—or should—be brought in-house.

Start With the Prescriptions Already Leaving the Organization

Before pursuing accreditation or making a major investment in infrastructure, a hospital should understand its existing specialty medication activity.

Which specialty medications are its providers prescribing?

Which therapies are being administered through its infusion or oncology programs?

Where are patients currently obtaining their specialty prescriptions?

Which prescriptions are being transferred or mandated to outside specialty pharmacies?

Which payer or manufacturer restrictions are driving those decisions?

The answers can help an organization determine whether there is enough opportunity to justify a more formal specialty pharmacy strategy.

For a hospital that already operates an outpatient pharmacy and treats a meaningful population of specialty patients, even a relatively small number of high-cost prescriptions may warrant a closer look.

Accreditation Is Important—but It Isn't the Starting Point

Organizations sometimes begin the specialty pharmacy conversation by asking whether they need URAC or another accreditation.

That question matters, but it comes later.

Accreditation can be an important component of payer contracting, network participation, manufacturer relationships, and demonstrating a mature specialty pharmacy program.

However, accreditation alone does not create access to every specialty network or guarantee that an organization can dispense every limited-distribution medication.

Before investing in accreditation, a hospital should understand the broader business and operational strategy.

That includes evaluating its patient and prescription opportunity, payer mix, existing pharmacy operations, staffing, technology, patient-management capabilities, licensing requirements, 340B structure, and potential network-access barriers.

Only then can the organization determine what accreditation and regulatory pathway supports the strategy.

Rural Hospitals May Be Better Positioned Than They Realize

CAHs, RRCs, and SCHs vary significantly in size, structure, and the populations they serve, but they often share an important characteristic: they serve as essential access points for patients who may have limited alternatives for care.

Many have longstanding relationships with their patients and providers, and some already manage a significant portion of a specialty patient's care within the same organization—from diagnosis and prescribing to laboratory monitoring, infusion services, and follow-up.

When specialty prescriptions leave that system, an important component of the patient's medication experience leaves with them.

That doesn't mean every rural hospital should bring specialty dispensing in-house. Payer networks, manufacturer restrictions, staffing, technology, accreditation, licensing, and prescription volume can all affect whether the model is viable.

But hospitals that already have pharmacy operations, specialty providers, infusion services, or significant specialty-drug utilization may be closer to a viable specialty pharmacy strategy than they realize.

The First Step Is a Feasibility Assessment

Not every CAH, RRC, or SCH should build a specialty pharmacy program.

That's precisely why the first step shouldn't be accreditation.

A specialty pharmacy feasibility assessment can examine the organization's existing pharmacy and clinical infrastructure, specialty prescription activity, 340B participation, payer environment, licensing considerations, operational gaps, and likely accreditation requirements.

The goal is to answer a much more fundamental question:

Is there a viable specialty pharmacy opportunity here—and, if so, what would it realistically take to pursue it?

For rural hospitals already investing in outpatient pharmacy, infusion, oncology, or other specialty-care services, that question may be worth asking.

About HVRS Solutions

HVRS Solutions helps pharmacies and healthcare organizations navigate pharmacy licensing, regulatory compliance, specialty pharmacy accreditation, 340B-related pharmacy operations, and the development of compliant pharmacy programs. Our team works with organizations nationwide to evaluate regulatory requirements and turn pharmacy growth opportunities into practical implementation strategies.